Completed PHASE2 INTERVENTIONAL 1-arm NCT02249130

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Tipranavir (PNU-140690): A Fourteen Day Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients. Report on the Post-study Option, a 46-week Treatment Period of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Sponsor: Boehringer Ingelheim

Conditions HIV Infections

Interventions Delavirdine (DLV) Lamivudine (3TC) Ritonavir (RTV) Stavudine (d4T) Tipranavir (TPV) Zidovudine (ZDV)

Updated 4 times since 2017 Last updated: Sep 23, 2014 Started: Mar 31, 1999 Primary completion: Apr 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HIV Infections and is currently completed. Boehringer Ingelheim leads this study, which shows 4 recorded versions since 1999 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.